TRP-601

Cat. No.:	HY-P2012
CAS No.:	1094569-02-4
Molecular Formula:	$C_{40}H_{48}F_2N_6O_{11}$
Molecular Weight:	826.84
Target:	Caspase; Bcl-2 Family
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	TRP-601 is a caspase inhibitor. TRP-601 reversed the increased expression of active caspase-2, the activation of endogenous apoptotic pathway and the up-regulation of key protein triggered by hyperoxia[1].

IC_{50} & Target	Caspase-2	Caspase 3	Bcl-2

In Vivo

TRP-601 (1 mg/kg, Intraperitoneal injection, single dose) reduces hyperoxia-induced caspase activation in rats, attenuates neuronal cell death in the developing brain in rats and inhibits intrinsic apoptotic signaling[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Wistar rats [1]
Dosage:	1 mg/kg
Administration:	Intraperitoneal injection (i.p.)
Result:	Ameliorated the increase of caspase-3 activity and reduced protein expression of processed caspase-2 and enzymatic activity. Significantly reduced neuronal cell death and did not influence levels of physiological apoptosis. Decreased Apaf-1 protein expression to control levels. Increased mRNA expression of Bcl-2.

REFERENCES

[1]. M Sifringer, et al. Prevention of neonatal oxygen-induced brain damage by reduction of intrinsic apoptosis. Cell Death Dis. 2012 Jan 12;3(1):e250.

[2]. Sifringer M, et al. Prevention of neonatal oxygen-induced brain damage by reduction of intrinsic apoptosis [J]. Cell death & disease, 2012, 3(1): e250-e250.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA